m
Recent Posts
Connect with:
Tuesday / August 9.
HomeminewsCooperVision Presents Six-Year MiSight 1 Day Data

CooperVision Presents Six-Year MiSight 1 Day Data

The latest findings from CooperVision’s landmark MiSight 1 day clinical study show that nearly one in four children’s eyes originally fit with the contact lens remain stable for myopia after six years.1

Paul Chamberlain, CooperVision’s Director of Research Programs, presented details of the study at a paper presentation1 at the American Academy of Optometry’s virtual annual meeting on 9 October 2020.

“Evaluating children who were prescribed MiSight 1 day at the study’s initiation, 23% of eyes after year six displayed a total refractive change of less than -0.25D (spherical equivalent), which could be considered clinically stable,” said Mr Chamberlain.1 “There is now even more reason to recognise the substantial capability of this unique dual-focus contact lens.”

Evaluating children who were prescribed MiSight 1 day at the study’s initiation, 23% of eyes after year six displayed a total refractive change of less than -0.25D

The newest findings also suggest that while intervention at an early age is optimal with MiSight 1 day, commencing treatment at an older age could similarly slow the rate of myopia progression.1 The original control group was refit into the dual-focus lens in year four. Comparing this population to the children fit with MiSight 1 day at initiation, there have been similar rates of myopia progression and axial length growth in the subsequent three years of assessment.1

Six-year results continue to demonstrate excellent safety profile, wearing time, and visual acuity for children in daily disposable contact lenses over 653 wearing years.1 No other prospective randomised controlled study has offered conclusive data for such a high degree of continued efficacy in myopia management using a soft contact lens over a similar time span.

Myopia is projected to affect the vision and increase risks to ocular health of approximately five billion people by 2050, more than doubling today’s numbers.2 Myopic progression has been linked to sight-threatening conditions later in life such as cataracts, retinal detachment, glaucoma3 and myopic maculopathy.4

Age Explored

Age was further explored in an Academy virtual poster session. Effects of Age on Myopia Progression with Dual-Focus and Single Vision Daily Disposable Contact Lenses (Arumugam et al., 2020) concluded that observed treatment effects in myopia management clinical trials may be dependent on the age of the subjects and study duration. Annual axial elongation rates were slowed by wearing MiSight 1 day during every year for ages eight to14 and myopia progression significantly slowed for ages eight to 13. These results also emphasised the importance of early intervention to slow pathological growth during years of more rapid progression. Early intervention also allowed an accumulating management effect over more years, resulting in greater total outcomes.

CooperVision MiSight 1 day is the first and only soft contact lens the U.S. Food and Drug Administration has approved* for slowing the progression of myopia in children, who at initiation of treatment are eight to 12 years of age.5 It is the centrepiece of the company’s Brilliant Futures Myopia Management Program, in which more than 1,000 U.S. ECPs are now certified. Versions of this comprehensive program are presently being introduced in other countries, including the United Kingdom, Canada, Spain and Portugal.

Reporting six-year data at Academy 2020 and ongoing research are part of a series of far-reaching initiatives by CooperVision to help educate eye care and healthcare professionals about advances in myopia management, including widespread conference participation, study support, clinical training events and more.

“As far as we have come with myopia management in recent years, there remains much to be done, including deeper partnerships with the optometry, ophthalmology and public health communities,” said James Gardner, Vice President for Global Myopia Management at CooperVision. “We’re a steadfast advocate for evidence-based advancements. I believe the six-year results will further our scientific understanding of myopia progression and increase clinical enthusiasm for proven management options such as MiSight 1 day.”

 

*  Indications for use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

 

References

  1. Chamberlain P, Logan N, Jones D, Gonzalez-Meijome J, Saw S-M, Young G. Clinical evaluation of a dual-focus myopia control 1 day soft contact lens: 6-year results (2020 American Academy of Optometry Annual Meeting).
  2. Holden et al, – Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-1042
  3. What You Should Know if Your Child is Nearsighted (Infographic). Retrieved October 29, 2019 from: https://www.allaboutvision.com/parents/myopia-facts-infographic.htm
  4. Macular Society. Myopia, Pathological Myopia and Myopic Macular Degeneration. Retrieved October 29, 2019 from: https://www.macularsociety.org/sites/default/files/resource/Macular%20Society%20Factsheet%20-%20Myopic%20Macular%20Degeneration%202020_0.pdf
  1. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567. Compared to a single vision 1 day lens over a 3 year period

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.